Stock Markets June 9, 2026 03:03 AM

Oxford Instruments posts modest revenue beat and robust order intake

Sales and adjusted operating profit top analyst expectations as order book extends into fiscal 2028

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn

Oxford Instruments reported preliminary full-year revenue of

Oxford Instruments posts modest revenue beat and robust order intake
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Preliminary full-year revenue of
  • Adjusted operating profit of
  • Advanced Technologies orders rose 28% and the order book covers planned revenue for fiscal 2027 with orders extending into fiscal 2028

Overview

Oxford Instruments announced preliminary full-year results showing revenue of

Financial highlights

The group's preliminary full-year revenue was reported at

Adjusted operating profit for the year came in at

The adjusted operating margin was 17.40% for the period. During the year the company completed the sale of its NanoScience division and returned capital to shareholders through

Orders and segment performance

Orders in the Advanced Technologies division grew by 28% over the year, a rise the company said provides visibility into future revenues and supports growth. Management reported the order book now covers planned revenue for fiscal year 2027, with purchase orders extending into fiscal year 2028.

The Imaging & Analysis segment delivered margin improvement and profit growth. The company attributed this to the restructuring of its Belfast cameras and microscopy operations and to improved operational execution.

Management noted the divestment of NanoScience contributed to an improvement in the group's operating margin and allowed the firm to concentrate on higher value growth opportunities.

Outlook and investment plans

Oxford Instruments reiterated confidence in achieving a medium-term organic revenue compound annual growth rate target of 5% to 8%. The company also said it plans to raise research and development investment in fiscal year 2027.


Note on disclosure

No additional disclosures were provided in the company statement included in these results.

Risks

  • The medium-term organic revenue CAGR of 5% to 8% is stated as a target in the company's announcement rather than a guaranteed outcome.
  • The company disclosed plans to increase R&D spending in fiscal year 2027 but did not provide detailed quantification of the impact of that higher investment on future operating results.
  • While management said the NanoScience divestment improved group operating margin, the company did not provide detailed metrics showing how consistently that improvement will be sustained across future periods.

More from Stock Markets

House Democrats File Resolution to Block U.S.-Saudi Civil Nuclear Pact Sep 17, 2026 QQQ Keeps Oscillating Around 50-Day Average as Nasdaq-100 Holds Flat Sep 17, 2026 U.K. Equities Close Higher as Mining, Utilities and Retail Lead Gains Sep 17, 2026 AngloGold Ashanti Shares Rise Ahead of U.S. Open as Gold and Analyst Revisions Lift Sentiment Sep 17, 2026 Final Hours to Lock in 55% Off InvestingPro Subscription Sep 17, 2026